March 22nd 2023
Retifanlimab has received accelerated approved for patients with metastatic or recurrent, locally advanced merkel cell carcinoma.
December 23rd 2022
Rise of Oral Cancer Drugs Signal Deeper Financial Toxicity Issues for Patients
September 28th 2022Mary Anderson, BSN, RN, OCN; and Christina Bach, MBE, MSW, LCSW, OSW-C, FAOSW, discuss approaches to help patients navigate financial toxicity and insurance coverage in the age of oral anticancer drugs.
Pembrolizumab Potentially Most Effective Before Surgery in High-Risk Melanoma
September 18th 2022The rate of event-free survival associated with pembrolizumab was significantly higher among patients with high-risk melanoma about to undergo surgery than among those who received immunotherapy following surgery.
5-Year Follow-Up Shows Neoadjuvant T-VEC Benefit in Patients with Resectable Melanoma
September 13th 2022The relapse-free survival rate was 22.3% among patients with resectable stage IIIB to IV M1a melanoma who received neoadjuvant talimogene laherparepvec versus 15.2% among those who received surgery alone.
7.5-Year Follow-Up Affirms Nivolumab’s Superiority Over Ipilimumab in Advanced Melanoma
July 13th 2022Nivolumab, whether in combination with ipilimumab or as a monotherapy, was associated with improved overall survival, progression-free survival, and melanoma-specific survival, compared with ipilimumab in advanced melanoma.